Meeting
2024 ASCO Annual Meeting
Phase II study in pediatric and AYA patients with non-metastatic high-grade extremity osteosarcoma with a risk-adapted strategy based on P-glycoprotein (ISG/OS-2): A correlative study on tumour immune microenvironment.
Authors
Emanuela Palmerini
Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies - IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
Emanuela Palmerini , Maria Rosaria Sapienza , Stefano A Pileri , Alberto Righi , Antonina Parafioriti , Alessandro Franchi , Claudio Agostinelli , Cristina Meazza , Virginia Ferraresi , Sebastian Dorin Asaftei , Luca Coccoli , Angela Tamburini , Marco Gambarotti , Massimo Serra , Davide Maria Donati , Franca Fagioli , Marilena Cesari , Katia Scotlandi , Maria Antonella Laginestra , Toni Ibrahim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Bone Tumors
Clinical Trial Registration Number
NCT03737435
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 11530)
DOI
10.1200/JCO.2024.42.16_suppl.11530
Abstract #
11530
Poster Bd #
456
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.
First Author: Damon R. Reed
Poster
2023 ASCO Annual Meeting
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
First Author: Florian Guisier
Poster
2022 ASCO Annual Meeting
A phase 1/2 dose-escalation and dose-expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric subjects with relapsed or refractory osteosarcoma.
First Author: Viswatej Avutu
Poster
2022 ASCO Annual Meeting
A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes.
First Author: Neeta Somaiah